A phase II, randomised, double blind, placebo controlled, three way crossover study to assess the bronchodilator effect of RPL554 administered in addition to open label tiotropium in patients with COPD
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2018
At a glance
- Drugs RPL 554 (Primary) ; Tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Verona Pharma
- 30 Aug 2018 Results of pooled data from two trials (NCT02542254 and NCT03028142), were published in the European Respiratory Journal.
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society.
- 21 May 2018 Results presented in a Verona Pharma media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History